Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone
- PMID: 19243544
- PMCID: PMC3424604
- DOI: 10.1111/j.1537-2995.2008.01983.x
Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone
Abstract
Background: The combination of granulocyte-colony-stimulating factor (G-CSF) and dexamethasone is an effective granulocyte mobilization regimen. The short-term side effects of G-CSF are well studied, but the potential long-term effects of repeated G-CSF stimulation in unrelated volunteer granulocyte donors have not been reported.
Study design and methods: Donors who had received G-CSF three or more times for granulocytapheresis between 1994 and 2002 were identified and attempts were made to contact them if they were no longer active donors. They were matched with control platelet (PLT) donors for sex, age, and approximate number of cytapheresis donations. A health history was obtained and complete blood counts (CBCs) and C-reactive protein (CRP) determined where feasible.
Results: Ninety-two granulocyte donors were identified, and 83 of them were contacted. They contributed to 1120 granulocyte concentrates, or a mean of 13.5 granulocytapheresis procedures per donor (and a mean of 87.5 plateletpheresis procedures per donor). There was no difference in CBCs between the granulocyte donors and the control PLT donors. There was no difference in CRP between the two groups, and no difference in pre- and post-G-CSF CRP in a subset of 22 granulocyte donors. Predefined health events included malignancies, coronary artery disease, and thrombosis. At a median 10-year follow-up, there were seven such events in the granulocyte donors and five in the PLT donors.
Conclusion: Although the number of granulocyte donors studied is small and continued surveillance of healthy individuals after G-CSF is prudent, our data suggest that G-CSF/dexamethasone stimulation appears to be safe.
Conflict of interest statement
The authors have no conflict to disclose.
Similar articles
-
The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor: a 13-year experience.Transfusion. 2009 Mar;49(3):421-6. doi: 10.1111/j.1537-2995.2008.01997.x. Epub 2008 Nov 19. Transfusion. 2009. PMID: 19040597 Free PMC article.
-
Factors influencing white blood cell mobilisation in healthy granulocyte donors.Transfus Med. 2025 Apr;35(2):177-183. doi: 10.1111/tme.13115. Epub 2024 Nov 27. Transfus Med. 2025. PMID: 39601217
-
Characterization of buffy coat-derived granulocytes for clinical use: a comparison with granulocyte colony-stimulating factor/dexamethasone-pretreated donor-derived products.Vox Sang. 2017 Feb;112(2):173-182. doi: 10.1111/vox.12481. Epub 2017 Jan 25. Vox Sang. 2017. PMID: 28120426
-
An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor.Arch Pathol Lab Med. 1999 Jun;123(6):508-13. doi: 10.5858/1999-123-0508-AEOEIR. Arch Pathol Lab Med. 1999. PMID: 10383803 Review.
-
Granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor for collection of peripheral blood progenitor cells from healthy donors.Curr Opin Hematol. 2000 May;7(3):150-5. doi: 10.1097/00062752-200005000-00004. Curr Opin Hematol. 2000. PMID: 10786651 Review.
Cited by
-
Granulocyte transfusion therapy: randomization after all?Haematologica. 2009 Dec;94(12):1644-8. doi: 10.3324/haematol.2009.013680. Haematologica. 2009. PMID: 19996116 Free PMC article.
-
Cancer incidence in healthy Swedish peripheral blood stem cell donors.Bone Marrow Transplant. 2022 May;57(5):795-802. doi: 10.1038/s41409-022-01617-6. Epub 2022 Mar 7. Bone Marrow Transplant. 2022. PMID: 35256742 Free PMC article.
-
Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversies.J Transl Med. 2015 Nov 16;13:362. doi: 10.1186/s12967-015-0724-5. J Transl Med. 2015. PMID: 26572736 Free PMC article. Review.
-
Guidelines for safety management of granulocyte transfusion in Japan.Int J Hematol. 2010 Mar;91(2):201-8. doi: 10.1007/s12185-010-0506-z. Epub 2010 Feb 11. Int J Hematol. 2010. PMID: 20146029
-
Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors.Transfusion. 2012 Mar;52(3):537-41. doi: 10.1111/j.1537-2995.2011.03313.x. Epub 2011 Aug 29. Transfusion. 2012. PMID: 21883270 Free PMC article.
References
-
- Caspar C, Seger R, Burger J, Gmur J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood. 1993;81:2866–2871. - PubMed
-
- Liles WC, Huang JE, Llewellyn C, SenGupta D, Price TH, Dale DC. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion. 1997;37:182–187. - PubMed
-
- Price TH, Bowden RA, Boechkh M, Bux J, Nelson K, Liles WC, Dale DC. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95:3302–3309. - PubMed
-
- Stroncek DF, Yau YY, Oblitas J, Leitman SF. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. Transfusion. 2001;41:1037–1044. - PubMed
-
- Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD, Bensinger WI. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant. 2000;25:85–89. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous